Sfoglia per AUTORE
MAJOLINO I
Collezione AO Ordine Mauriziano

  

Items : 4

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib- melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment in Blood

2011
AO Ordine Mauriziano

Morabito F; Gentile M; Mazzone C; Rossi D; Di Raimondo F; Bringhen S; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci MT; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Montefusco V; Musto P; Cascavilla N; Majolino I; Musolino C; Cavo M; Boccadoro M; Palumbo A;

VMPT (bortezomib, melphalan, prednisone and thalidomide) followed by maintenance with bortezomib-thalidomide (VT) is active and well tolerated in newly diagnosed patients with multiple myeloma (MM) with moderate renal impairment (RI) ineligible for autologous stem cell transplantation: Results from a cohort analysis of a phase III randomized controlled trial in Haematologica

2011
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Morabito F; Gentile M; Mazzone C; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci M; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Musto P; Liberati A; Cascavilla N; Cangialosi C; Majolino I; Musolino C; Zambello R; Di Raimondo F; Cavo M; Boccadoro M; Palumbo A;

High response rate with favorable survival projections in high-risk patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP-14 or early intensified chemotherapy with rituximab and autograft (R-HDS): Results of the interim analysis of a gitil prospective multicenter phase III study in Blood

2009
AO Ordine Mauriziano

Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Zanni M; Corradini P; Di Nicola M; Patti C; Mulè A; Majolino I; Billio A; Gueli A; Di Raimondo F; Chiarenza A; Gallamini A; Ferreri A; Pizzolo G; Benedetti F; La Nasa G; Leoni P; Gini G; Trentin L; Rodeghiero F; Marchioli R; Barbui T; Barbui A; Rambaldi A;

Histology and rituximab addition are the main factors influencing the long-term outcome in high-risk lymphoma following high-dose therapy and autograft: A 20-yr. Follow-up in 1,347 patients by gitil (gruppo italiano terapie innovative NEI Linfomi) in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Di Nicola M; Rossi A; Caracciolo D; Passera R; Benedetti F; Patti C; Parvis G; Ciceri F; Castellino C; Cortelazzo S; Corradini P; Majolino I; Mule' A; Bosa M; Barbui A; Magni M; Boccadoro M; Sorio M; Rambaldi A; Gianni AM;